1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32220
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVerhoek, Andre-
dc.contributor.authorCheema, Parneet-
dc.contributor.authorMelosky, Barbara-
dc.contributor.authorSamson, Benoit-
dc.contributor.authorShepherd, Frances A-
dc.contributor.authorde Marinis, Filippo-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorWu, Yi-Long-
dc.contributor.authorHeeg, Bart-
dc.contributor.authorVan Dalfsen, Nadia-
dc.contributor.authorBracke, Benjamin-
dc.contributor.authorMiranda, Miguel-
dc.contributor.authorShaw, Simon-
dc.contributor.authorMoldaver, Daniel-
dc.date2023-
dc.date.accessioned2023-03-01T03:56:00Z-
dc.date.available2023-03-01T03:56:00Z-
dc.date.issued2023-02-22-
dc.identifier.citationPharmacoEconomics - Open 2023en_US
dc.identifier.issn2509-4254-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/32220-
dc.description.abstractFor many patients with resected epidermal growth factor receptor mutation-positive (EGFRm) non-small cell lung cancer (NSCLC), current standard of care (SoC) is adjuvant chemotherapy; however, disease recurrence remains high. Based on positive results from ADAURA (NCT02511106), adjuvant osimertinib was approved for treatment of resected stage IB‒IIIA EGFRm NSCLC.en_US
dc.language.isoeng-
dc.titleEvaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitlePharmacoEconomics - Openen_US
dc.identifier.affiliationWilliam Osler Health System, University of Toronto, Toronto, ON, Canada.en_US
dc.identifier.affiliationDepartment of Medical Oncology, BC Cancer, Vancouver, BC, Canada.en_US
dc.identifier.affiliationCharles LeMoyne Hospital Cancer Center, Greenfield Park, QC, Canada.en_US
dc.identifier.affiliationDepartment of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, ON, Canada.en_US
dc.identifier.affiliationDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.affiliationDepartment of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.en_US
dc.identifier.affiliationCytel, Weena 316-318, 3012 NJ, Rotterdam, The Netherlands.en_US
dc.identifier.affiliationGlobal Health Economics and Payer Evidence, AstraZeneca, Cambridge, UK.en_US
dc.identifier.affiliationGlobal Medical Development, AstraZeneca, Cambridge, UK.en_US
dc.identifier.affiliationGlobal Medical Affairs, AstraZeneca, Cambridge, UK.en_US
dc.identifier.affiliationHealth Economics and Payer Evidence, AstraZeneca, Mississauga, ON, Canada.en_US
dc.identifier.doi10.1007/s41669-023-00396-0en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3958-0033en_US
dc.identifier.pubmedid36811822-
local.name.researcherJohn, Thomas
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Oct 2, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.